Evommune, Inc.
EVMNNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| Operating income | −$81.1M | −$70.0M |
| Net income | −$68.9M | −$66.8M |
| Total assets | $224.9M | $76.1M |
| Total liabilities | $19.4M | $28.5M |
| Equity | $205.6M | −$144.2M |
| EPS (diluted) | $-11.22 | $-45.29 |
| Shares out. | 31.5M | 1.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −623.6%
- Net margin
- −529.8%
- Return on equity
- −33.5%
- Return on assets
- −30.6%
- Return on capital (ROCE)
- −39.2%
- Liabilities / assets
- 8.6%
- Debt / equity
- 0.09×
- Book value / share
- $6.52
- Revenue growth (YoY)
- 85.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 9.47safe
- Accruals / assets
- 3.4%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-06Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
- Phase 2Active Not Recruitingreadout ~2026-07Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
- Phase 2Not Yet Recruitingreadout ~2027-10Study of EVO756 in Adults With Migraine
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Lsp 7 Cooperative UaActivist (13D)Feb 19, 2026
- Ra Capital Management, L.P.Activist (13D)Feb 17, 2026
- Pivotal Bioventure Partners Fund I, L.P.Passive (13G)Feb 13, 2026
- Andera PartnersPassive (13G)Nov 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Moss Gregory S.Officer — Chief Business & Legal Officer | May 28, 2026 | Option exercise | 14,223 | $1.71 |
| Carver KyleOfficer — Chief Financial Officer | May 28, 2026 | Option exercise | 15,000 | $2.99 |
| Lsp 7 Cooperative UaDirector | Feb 17, 2026 | Grant | 358,680 | $27.88 |
| Verduyn-Van Weegen Felice IsabelDirector | Feb 17, 2026 | Grant | 358,680 | $27.88 |
| Ra Capital Management, L.P.Director | Feb 17, 2026 | Grant | 35,868 | $27.88 |
| Hopfner Robert LorneDirector | Dec 19, 2025 | Buy | 1,000 | $17.35 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.1M | 7.2 | -4.6% |
| Apr 30, 2026 | 3.2M | 13.3 | -6.1% |
| Apr 15, 2026 | 3.5M | 11.0 | +4.6% |
| Mar 31, 2026 | 3.3M | 9.1 | +8.0% |
| Mar 13, 2026 | 3.1M | 11.9 | +1.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 7, 2026
- Regulation FD disclosureApr 13, 2026
- Results of operationsMar 5, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureFeb 13, 2026
- Regulation FD disclosureFeb 10, 2026
- Results of operationsDec 11, 2025
- Amended charter or bylawsNov 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.